Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge advises Symrise on its mandatory bid for Swedencare

Symrise AG has made a public mandatory bid for all shares in Swedencare AB (publ).
June 07, 2023

Vinge advises Stride.VC in connection with its investment in Anotherblock

In 2022, Anotherblock launched a blockchain-based marketplace for music rights. The company has through its platform granted fans access to streaming rights from several known artists. The investment round is led by Stride.VC.
May 25, 2023

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.
May 22, 2023